Mineralys Therapeutics (MLYS) Cash from Financing Activities (2022 - 2026)
Quarterly results put Cash from Financing Activities at $24.3 million for Q1 2026, down 87.18% from a year ago — trailing twelve months through Mar 2026 was $426.0 million (up 125.14% YoY), and the annual figure for FY2025 was $591.0 million, up 408.86%.
Mineralys Therapeutics has reported Cash from Financing Activities over the past 5 years, most recently at $24.3 million for Q1 2026.
- Cash from Financing Activities reached $24.3 million in Q1 2026 per MLYS's latest filing, down from $96.7 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $295.2 million in Q3 2025 and bottomed at -$1.1 million in Q4 2022.
- Median Cash from Financing Activities over the past 5 years was $9.8 million (2025), compared with a mean of $62.5 million.
- The largest annual shift saw Cash from Financing Activities tumbled 100.54% in 2024 before it surged 29518900.0% in 2025.
- Over 5 years, Cash from Financing Activities stood at -$1.1 million in 2022, then soared by 106.93% to $74000.0 in 2023, then increased by 21.62% to $90000.0 in 2024, then surged by 107345.56% to $96.7 million in 2025, then plummeted by 74.9% to $24.3 million in 2026.
- Business Quant data shows Cash from Financing Activities for MLYS at $24.3 million in Q1 2026, $96.7 million in Q4 2025, and $295.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | 24.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.27 Mn |
| Mar 31, 2026 | 24.27 Mn |
| Dec 31, 2025 | 96.70 Mn |
| Dec 31, 2025 | 96.70 Mn |
| Sep 30, 2025 | 295.19 Mn |
| Sep 30, 2025 | 295.19 Mn |
| Jun 30, 2025 | 9.83 Mn |
| Jun 30, 2025 | 9.83 Mn |
| Mar 31, 2025 | 189.28 Mn |
| Mar 31, 2025 | 189.28 Mn |
| Dec 31, 2024 | 90,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -152,000.00 |
| Jun 30, 2024 | -152,000.00 |
| Mar 31, 2024 | 116.21 Mn |
| Mar 31, 2024 | 116.21 Mn |
| Dec 31, 2023 | 74,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 184,000.00 |
| Sep 30, 2023 | 184,000.00 |
| Jun 30, 2023 | -581,000.00 |
| Jun 30, 2023 | -581,000.00 |
| Mar 31, 2023 | 203.57 Mn |
| Mar 31, 2023 | 203.57 Mn |
| Dec 31, 2022 | -1.07 Mn |
| Dec 31, 2022 | -1.07 Mn |
| Sep 30, 2022 | -561,000.00 |
| Sep 30, 2022 | -561,000.00 |
| Jun 30, 2022 | 117.65 Mn |
| Jun 30, 2022 | 117.65 Mn |
| Mar 31, 2022 | 12.00 Mn |
| Mar 31, 2022 | 12.00 Mn |